TABLE 2.
Baseline patient characteristics in the included trials.
| Author | Year | Comparison | BMI (kg/m2) | ASA (i/II/III) | Hypotension history | Diabetes history | Cardiovascular and cerebrovascular diseases | Mean age ±SD | Male/female | Number of patients | Endoscopy type (no. of patients) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chen et al. | 2023 | Ciprofol group | 23.41 ± 2.77 | 12/12/14 | NA | NA | NA | 52.03 ± 13.54 | 22/16 | 38 | Gastroscopy (20), colonoscopy (18) |
| Ciprofol group | 22.65 ± 3.53 | 15/10/11 | NA | NA | NA | 45.58 ± 17.04 | 12/24 | 36 | Gastroscopy (21), colonoscopy (15) | ||
| Ciprofol group | 22.99 ± 3.01 | 14/12/5 | NA | NA | NA | 47.45 ± 11.90 | 11/20 | 31 | Gastroscopy (18), colonoscopy (13) | ||
| Propofol group | 22.16 ± 3.06 | 19/19/6 | NA | NA | NA | 43.55 ± 16.19 | 18/26 | 44 | Gastroscopy (31) Colonoscopy (13) |
||
| Chen et al. | 2022 | Ciprofol group | 25.22 ± 10.12 | NA | NA | NA | NA | 41.22 ± 11.63 | 22/25 | 47 | Gastrointestinal endoscopy (47) |
| Propofol group | 23.46 ± 3.43 | 43/6/0 | NA | NA | NA | 43.20 ± 12.29 | 17/32 | 49 | Gastrointestinal endoscopy (49) | ||
| Gao et al. | 2024 | Ciprofol group | 23.4 ± 3.0 | 16/66/0 | NA | NA | NA | 52.50 ± 10.50 | 34/48 | 82 | Colonoscopy (82) |
| Propofol group | 23.7 ± 3.0 | 20/62/0 | NA | NA | NA | 53.50 ± 9.50 | 32/50 | 82 | Colonoscopy (82) | ||
| He et al. | 2024 | Ciprofol group | 23.7 ± 2.9 | 29/81/0 | 17/93 | 5/105 | 1/109 | 48.00 ± 11.20 | 54/56 | 110 | Colonoscopy (110) |
| Propofol group | 23.8 ± 2.7 | 36/76/0 | 16/96 | 5/107 | 2/110 | 49.00 ± 9.70 | 46/66 | 112 | Colonoscopy (112) | ||
| Li et al. | 2022 | Ciprofol group | 23.2 ± 2.5 | 115/29/0 | NA | NA | NA | 43.8 ± 11.80 | 55/89 | 144 | Gastroscopy (15), colonoscopy (129) |
| Propofol group | 23.4 ± 2.6 | 118/27/0 | NA | NA | NA | 44.1 ± 11.30 | 63/82 | 145 | Gastroscopy (15) Colonoscopy (130) |
||
| Li et al. | 2024 | Ciprofol group | 23.19 ± 3.01 | 70/38/0 | 44/64 | 19/89 | 4/104 | 46.36 ± 11.20 | 48/60 | 108 | Gastroscopy (108) |
| Propofol group | 23.42 ± 2.79 | 71/38/0 | 41/68 | 23/86 | 10/99 | 47.34 ± 12.33 | 49/60 | 109 | Gastroscopy (109) | ||
| Liao et al. | 2023 | Ciprofol group | 23.07 ± 2.28 | 79/106/0 | NA | NA | NA | 44.98 ± 11.74 | 87/98 | 185 | Gastroscopy (99), gastrointestinal endoscopy (86) |
| Propofol group | 23.13 ± 2.23 | 62/121/0 | NA | NA | NA | 45.35 ± 11.12 | 77/106 | 183 | Gastroscopy (94), gastrointestinal endoscopy (89) | ||
| Liu et al. | 2024 | Ciprofol group | 23.00 ± 2.86 | NA | NA | NA | NA | 45.63 ± 10.07 | 13/17 | 30 | Gastroscopy (30) |
| Propofol group | 23.69 ± 2.62 | NA | NA | NA | NA | 45.00 ± 12.96 | 18/12 | 30 | Gastroscopy (30) | ||
| Teng et al. | 2021 | Ciprofol group | NA | 25/6/0 | NA | NA | NA | 46.20 ± 13.00 | 12/19 | 31 | Colonoscopy (31) |
| Ciprofol group | NA | 25/7/0 | NA | NA | NA | 47.50 ± 15.20 | 14/18 | 32 | Colonoscopy (32) | ||
| Propofol group | NA | 25/6/0 | NA | NA | NA | 48.40 ± 13.70 | 16/15 | 31 | Colonoscopy (31) | ||
| Zhang et al. | 2024 | Ciprofol group | 23.40 ± 3.3 | 75/18/0 | 18/75 | 4/89 | 17/76 | 54.00 ± 11.10 | 52/41 | 93 | Gastrointestinal endoscopy (93) |
| Propofol group | 23.30 ± 3.2 | 69/23/0 | 27/65 | 6/86 | 10/82 | 51.60 ± 11.10 | 52/40 | 92 | Gastrointestinal endoscopy (92) | ||
| Zhou et al. | 2024 | Ciprofol group | NA | NA | NA | NA | NA | 48.02 ± 12.05 | 52/68 | 120 | Gastroscopy (38), colonoscopy (16), Gastrointestinal endoscopy (66) |
| Propofol group | NA | NA | NA | NA | NA | 48.72 ± 9.97 | 66/54 | 120 | Gastroscopy (34), colonoscopy (18), Gastrointestinal endoscopy (68) |
Abbreviations: NA, not available; BMI, body mass index; ASA, american society of anesthesiologists; SD, standard deviation.